You have 9 free searches left this month | for more free features.

Margetuximab

Showing 1 - 7 of 7

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Breast Cancer, Advanced Breast Cancer, HER2-positive Breast Cancer Trial (Margetuximab, Tucatinib, Capecitabine)

Withdrawn
  • Metastatic Breast Cancer
  • +2 more
  • Margetuximab
  • +2 more
  • (no location specified)
Jul 6, 2022

HER2-positive Breast Cancer, HER2-positive Carcinoma Trial (Margetuximab)

Approved for marketing
  • HER2-positive Breast Cancer
  • HER2-positive Carcinoma
  • Margetuximab
  • (no location specified)
Feb 21, 2022

HER2 Positive Metastatic Breast Cancer Trial in Beijing, Shijiazhuang, Zhengzhou (Margetuximab Margetuximab-IV)

Completed
  • HER2 Positive Metastatic Breast Cancer
  • Margetuximab Margetuximab-IV
  • Beijing, Beijing, China
  • +2 more
Jun 11, 2021

Breast Cancer Trial in United States (Margetuximab)

Completed
  • Breast Cancer
  • Margetuximab
  • San Francisco, California
  • +5 more
Feb 4, 2022

Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer Trial in Worldwide (margetuximab, Retifanlimab,

Active, not recruiting
  • Gastric Cancer
  • +2 more
  • margetuximab
  • +4 more
  • Scottsdale, Arizona
  • +72 more
Aug 24, 2022

Breast Cancer Metastatic Trial in Taipei (Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine))

Unknown status
  • Breast Cancer Metastatic
  • Margetuximab
  • +4 more
  • Taipei, Taiwan
    National Taiwan University Hospital
Feb 6, 2020

HER-2 Positive Breast Cancer, Metastatic Tumor Trial in Worldwide (Margetuximab, Trastuzumab, Capecitabine)

Active, not recruiting
  • HER-2 Positive Breast Cancer
  • Metastatic Neoplasm
  • Margetuximab
  • +5 more
  • Chandler, Arizona
  • +166 more
Oct 18, 2021